HCPCS Level II code J1305 denotes injection of evinacumab-dgnb in 5 mg units, an injectable biologic therapy used in specialty lipid management and related indications. Nationally, accurate coding for high-cost biologic agents like evinacumab is critical for claims adjudication, benefit design, and utilization oversight. This code establishes unit-based billing for the drug component separate from administration services.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical role and billing context, payer coverage focus, and practical considerations for service setting and unitization. The publication outlines benchmarks for unit reporting, common modifiers associated with drug billing, and policy updates affecting reimbursement and prior authorization practices.

The article provides clinicians, billing staff, and policy analysts with clear information about what J1305 represents, where the service is typically delivered, and which major payers are relevant to coverage discussions. It also identifies where input data are absent and directs readers to review payer-specific medical and pharmacy policies for detailed coverage criteria and fee schedules.